An investor asked on the investor interaction platform: does the company cooperate with shuotang? Does the company intend to enter the aquatic vaccine market? In addition, on August 4, 2021, the interactive said that the new aureomycin workshop will be put into operation in the second half of the year. What’s the situation now?
Jinhe Biotechnology Co.Ltd(002688) (002688. SZ) said on the investor interaction platform on January 24 that the company signed a total procurement agreement on the procurement volume of chlortetracycline from 2020 to 2024 with shuotang company, and the company currently has no aquatic vaccine market layout plan. In September 2021, the company’s “project with an annual output of 52000 tons of veterinary drug grade high-efficiency aureomycin and 1000 tons of aureomycin hydrochloride API” started laying the foundation, and is currently under construction as planned.
